EP. 2: Key Considerations in Treatment Selection for Patients With Multiple Myeloma
January 29th 2024Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.
Watch
EP. 4: Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
February 12th 2024Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.
Watch
EP. 5: The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
February 19th 2024Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.
Watch
EP. 7: Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
March 4th 2024Experts discuss challenges related to the implementation of bispecific antibodies for the treatment of multiple myeloma and emphasize the critical role of interinstitutional collaboration in developing bispecific antibody programs.
Watch
EP. 9: Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
March 11th 2024Michael Singel, PharmD; and Carol Ann Huff, MD, discuss how step-up dosing for bispecific antibodies has been implemented in the outpatient setting with monitoring considerations for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome to ensure patient safety.
Watch
EP. 10: Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
March 11th 2024Carol Ann Huff, MD, describes her institution's multidisciplinary approach to monitoring for adverse events when administering bispecific antibodies, including the roles of nurses, pharmacists, and attending physicians.
Watch
EP. 11: Complying with REMS Training and Documentation Requirements
March 19th 2024Michael Singel, PharmD, discusses the logistics of complying with the Risk Evaluation and Mitigation Strategy program for bispecific antibodies at his institution and addresses training and documentation requirements.
Watch
EP. 12: Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
March 19th 2024Michael Singel, PharmD, discusses the role of pharmacists in the operationalization of bispecifics to treat multiple myeloma, including the creation of treatment plans and standard of care order sets.
Watch
EP. 14: Treatment Sequencing and Combination Therapies for MM
March 26th 2024Carol Ann Huff, MD discusses how the approval of additional bispecific antibodies for multiple myeloma might change the treatment selection process, highlighting considerations for sequencing of agents and combination therapy.
Watch